The efficacy, safety, and tolerability of antipsychotics in the elderly

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 8, 1999, Pages 29-41

  Maixner, Susan M ^a   Mellow, Alan M ^a   Tandon, Rajiv ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; LOXAPINE SUCCINATE; OLANZAPINE; PROMAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; TRIHEXYPHENIDYL;

ANTICHOLINERGIC EFFECT; COGNITIVE DEFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; EYE DISEASE; HEART DISEASE; HUMAN; HYPERPROLACTINEMIA; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SEXUAL DYSFUNCTION; WEIGHT GAIN;

ACCIDENTAL FALLS; AGE FACTORS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CLINICAL TRIALS; CLOZAPINE; DRUG COSTS; DRUG INTERACTIONS; DYSKINESIA, DRUG-INDUCED; HUMANS; HYPERPROLACTINEMIA; OSTEOPOROSIS; PSYCHOTIC DISORDERS; WEIGHT GAIN;

EID: 0032956290     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (140)

1. Deamer RL, Thompson JF. The role of medications in geriatric sexual function. Clin Geriatr Med 1991;7:95-111
2. Ray WA, Federspiel CF, Schaffner W. A study of antipsychotic drug use in nursing homes: epidemiology evidence suggesting misuse. Am J Public Health 1980;70:485-491
3. Short RI, Fought RL, Ray WA. Changes in antipsychotic drug use in nursing homes during implementation of the OBRA-87 regulations. JAMA 1994;271:358-362
4. Nolan L, O'Malley K. Prescribing for the elderly, part II: prescribing patterns: differences due to age. J Am Geriatr Soc 1988;36:245-254
5. Woerner MG, Alvir JMJ, Saltz BL, et al. Prospective study of tardive dyskinesia in the elderly; rates and risk factors. Am J Psychiatry 1998;155: 1521-1528
6. Federal Drug Administration. Omnibus Budget Reconciliation Act Guidelines of 1987. 54 Federal Register. 1989:5316-5336
7. Salzman C, Vaccaro B, Lieff J, et al. Clozapine in older patients with psychosis and behavioral disruption. Am J Geriatr Psychiatry 1995;3:26-33
8. Sweet RA, Pollock BG. New atypical antipsychotics: experience and utility in the elderly. Drugs Aging 1998;12:115-127
9. Tandon R. Antipsychotic agents. In: Quitkin FM, Adams DC, Bowden CL, et al, eds. Current Psychotherapeutic Drugs. 2nd ed. Philadelphia, Pa: Current Medicine, Inc; 1998:120-154
10. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients. Arch Gen Psychiatry 1995;52:756-765
11. Kane JM. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington, DC: American Psychiatric Association; 1992
12. American Psychiatric Association. Task force on late neurological effects of antipsychotic drugs. Tardive dyskinesia: summary of a task force report of the American Psychiatric Association. Am J Psychiatry 1980;137: 1163-1172
13. Jeste DV, Wyatt RJ. Understanding and treating tardive dyskinesia. New York, NY: Guilford Press; 1982
14. Jeste DV, Caligiuri MP. Tardive dyskinesia. Schizophr Bull 1993;19: 303-315
15. Labbate LA, Lande RG, Jones F, et al. Tardive dyskinesia in older outpatients: a follow-up study. Acta Psychiatr Scand 1997;96:195-198
16. Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1997;58(suppl 10):55-62
17. Saltz BL, Woerner MG, Kane JM, et al. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991;266:2402-2406
18. Verhaeverbeke I, Mets T. Drug-induced orthostatic hypotension in the elderly: avoiding its onset. Drug Saf 1997;17:105-118
19. Nygaard HA. Falls and psychotropic drug consumption in long-term care residents: is there an obvious association? Gerontology 1998;44:46-50
20. Yip YB, Cumming RG. The association between medications and falls in Australian nursing-home residents. Med J Aust 194;160:14-18
21. Gales BJ, Menard SM. Relationship between the administration of selected medications and falls in hospitalized elderly patients. Ann Pharmacother 1995;29:354-358
22. Halbreich U, Palter S. Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Schizophr Bull 1996;22:447-454
23. Levinson DF, Simpson GM. Antipsychotic drug effects. In: Hales RE, Frances AJ, eds. Psychiatry Update: American Psychiatric Association Annual Review. Washington, DC: American Psychiatric Association; 1987: 707-723
24. Klibanski A, Neer RM, Beitins IZ, et al. Decreased bone density in hyperprolactinemic women. N Engl J Med 1980;303:1511-1514
25. Ataya K, Mercado A, Kartaginer J, et al. Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia. Fertil Steril 1988;50:876-881
26. Halbreich U, Rojansky M, Palter S, et al. Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 1995;57:485-491
27. Monane M, Avorn J, Beer MH, et al. Anticholinergic drug use and bowel function in nursing home patients. Arch Intern Med 1993;153:633-638
28. Alessi CA, Henderson CT. Constipation and fecal impaction in the long term care patient. Clin Geriatr Med 1988;4:571-588
29. Hyams DE. Gastrointestinal problems of the old. BMJ 1974;1:107-110
30. McWilliams WA, Khauli RB, Zein TA. Ureteral obstruction due to massive fecal impaction. South Med J 1984;77:275-276
31. McShane R, Keene J, Gedling K, et al. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ 1997;314:266-270
32. Berman I, Merson A, Allan F, et al. Effect of risperidone on cognitive performance in elderly schizophrenic patients: a double-blind comparison study with haloperidol [abstract]. Psychopharmacol Bull 1995;31:552
33. Street J, Clark WS, Mitan S, et al. Olanzapine in the treatment of psychiatric disturbances with Alzheimer's disease. Presented at the Annual Meeting of the American Academy of Neurology; April 17-24, 1998; Ontario, Canada
34. Perkins DO. Weight gain and the new antipsychotics. J Psychotic Disorders 1998;2:8-9
35. Stanton JM. Weight gain associated with neuroleptic medication: a review. Schizophr Bull 1995;21:463-472
36. Lapidus L, Bengtsson C, Larsson B, et al. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. BMJ 1984;289:1257-1261
37. Hartz AJ, Rupley DC, Rimm AA. The association of girth measurements with disease in 32,856 women. Am J Epidemiol 1984;119:71-80
38. Larsson B, Svardsudd K, Welin L, et al. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. BMJ 1984;12: 1401-1404
39. McManus DQ, Arvanitis LA, Kowalcyk BB, and the Seroquel Trial 48 Study Group. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. J Clin Psychiatry. In press
40. Yasuhara T, Nishida K, Uchida K, et al. Corneal endothelial changes in schizophrenic patients with long-term administration of major tranquilizers. Am J Ophthalmol 1996;121:84-88
41. Seroquel [package insert]. Wilmington, Del: Zeneca Pharmaceuticals; 1997
42. Tegretol [package insert]. Summit, NJ: Ciba-Geigy Corporation; 1997
43. Milner K, Tomori O, Florence T, et al. Psychotropic medications and sexual dysfunction. In: Buckley PF, ed. Sexuality Among Patients With Serious Mental Illness. Washington, DC: American Psychological Association Press. In press
44. Troutman WG. Drug-induced sexual dysfunction. In: Knoben JE, Anderson PO, eds. Handbook of Clinical Drug Data. Hamilton, Ill: Drug Intelligence Publications: 1988:112-119
45. McKenney JM, Harrison WL. Drug-related hospital admissions. Am J Hosp Pharm 1976;33:792-795
46. Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med 1990;150:841-845
47. Einarson TR. Drug-related hospital admissions. Ann Pharmacother 1993; 27:832-840
48. Cooper JW. Probable adverse drug reactions in a rural geriatric nursing home population: a four-year study. J Am Geriatr Soc 1996;44:194-197
49. Pollock BG, Mulsant BH. Antipsychotics in older patients: a safety perspective. Drugs Aging 1995;6:312-323
50. Salzman C. Geriatric psychopharmacology. In: Gelenberg AJ, Bassuk EL, eds. The Practitioner's Guide to Psychoactive Drugs. 4th ed. New York, NY: Plenum Publishing; 1998:367-384
51. Barton R, Hurst L. Unnecessary use of tranquilizers in elderly patients. Br J Psychiatry 1966;112:989-990
52. Institute of Medicine CoNHR. Improving the Quality of Care in Nursing Homes. Washington, DC: National Academy Press; 1986
53. Lesseig DZ. Pharmacotherapy for long-term care residents with dementia-associated behavioral disturbance. J Psychosoc Nurs Ment Health Serv 1998;36:27-31
54. Streim JE, Katz IR. Federal regulations and the care of patients with dementia in the nursing home. Med Clin North Am 1994;78:895-909
55. Stoudemire A, Smith DA. OBRA regulations and the use of psychotropic drugs in long-term care facilities: impact and implications for geropsychiatric care. Gen Hosp Psychiatry 1996;18:77-94
56. Slater EJ, Glazer W. Use of OBRA-87 guidelines for prescribing neuroleptics in a VA nursing home. Psychiatr Serv 1995;46:119-121
57. Llorente MD, Olsen EJ, Leyva O, et al. Use of antipsychotic drugs in nursing homes: current compliance with OBRA regulations. J Am Geriatr Soc 1998;46:198-201
58. Lantz MS, Giambanco V, Buchalter EN. A ten-year review of the effect of OBRA-87 on psychotropic prescribing practices in an academic nursing home. Psychiatr Serv 1996;47:951-955
59. Borson S, Doane K. The impact of OBRA-87 on psychotropic drug prescribing in skilled nursing facilities. Psychiatr Serv 1997;48:1289-1296
60. Meltzer HY, Cola PA. The pharmacoeconomics of clozapine: a review. J Clin Psychiatry 1994;55(9, suppl B):161-165
61. Aronson SM. Cost-effectiveness and quality of life in psychosis: the pharmacoeconomics of risperidone. Clin Ther 1997;19:139-147; discussion 126-127
62. Hong WW, Rak IW, Ciuryla VT, et al. Medical-claims databases in the design of a health-outcomes comparison of quetiapine ("Seroquel") and usual-care antipsychotic medication. Schizophr Res 1998;32:51-58
63. Fichtner CG, Hanrahan P, Luchins DJ. Pharmacoeconomic studies of atypical antipsychotics: review and perspective. Psychiatr Ann 1998;28: 381-396
64. Saykin AJ, Gur RC, Gur RE, et al. Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch Gen Psychiatry 1991;48:618-624
65. Spohn HE, Strauss ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol 1989;98: 367-380
66. Marder SR, Asamow RF, Mintz J. Information processing and neuroleptic response in acute and stabilized schizophrenic patients. Psychiatr Res 1984;13:41-49
67. Tune LE, Strauss ME, Lew MF, et al. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am J Psychiatry 1982;139:1460-1462
68. Strauss ME, Reynolds KS, Jayaram G, et al. Effects of anticholinergic medication on memory in schizophrenia. Schizophr Res 1990;3:127-129
69. Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 1994;55(9, suppl B):82-87
70. McGurk SR, Green MF, Wirshing WC, et al. The effects of risperidone vs. haloperidol on cognitive functioning in treatment-resistant schizophrenia: the trail making test. CNS Spectrums 1997;2:60-64
71. Chatterjee A, Chakos M, Koreen A, et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 1995;152:1724-1729
72. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995;15: 36S-44S
73. Tollefson GD, Beasley CM, Tamura RN, et al. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997;154:1248-1254
74. Avom J, Soumerai SB, Everitt DE, et al. A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes. N Engl J Med 1992;327:168-173
75. Beardsley RS, Larson DB, Burns BJ, et al. Prescribing of psychotropics in elderly nursing home patients. J Am Geriatr Soc 1989;37:327-330
76. Beers M, Avorn J, Soumerai SB, et al. Psychoactive medication use in intermediate-care facility residents. JAMA 1988;260:3016-3020
77. Garrard J, Makris L, Dunham T, et al. Evaluation of neuroleptic drug use by nursing home elderly under proposed Medicare and Medicaid regulations. JAMA 1991;265:463-467
78. Garrard J, Dunham T, Makris L, et al. Longitudinal study of psychotropic drug use by elderly nursing home residents. J Gerontol 1992;47: M183-M188
79. Semla TP, Cohen D, Freels S, et al. Psychotropic drug use in relation to psychiatric symptoms in community-living persons with Alzheimer's disease. Pharmacotherapy 1995;15:495-501
80. Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990;38: 553-563
81. Sunderland T, Silver M. Neuroleptics in the treatment of dementia. Int J Geriatr Psychiatry 1988;3:79-88
82. Helms PM. Efficacy of antipsychotics in the treatment of the behavioral complications of dementia: a review of the literature. J Am Geriatr Soc 1985;33:206-209
83. Devanand DP, Nelson JC. Concurrent depression and dementia: implications for diagnosis and treatment. J Clin Psychiatry 1985;46:389-392
84. Tune LE, Steele C, Cooper T. Neuroleptic drugs in the management of behavioral symptoms of Alzheimer's disease. Psychiatr Clin North Am 1991;14:353-373
85. Raskind MA, Risse SC. Antipsychotic drugs and the elderly. J Clin Psychiatry 1986;47(5, suppl):17-22
86. Devanand DP, Sackeim HA, Mayeux R. Psychosis, behavioral disturbance, and the use of neuroleptics in dementia. Compr Psychiatry 1988; 29:387-401
87. Juncos JL. Management of psychotic aspects of Parkinson's disease. J Clin Psychiatry 1999;60(suppl 0):00-00
88. Branchey MH, Lee JH, Amin R, et al. High- and low-potency neuroleptics in elderly psychiatric patients. JAMA 1978;239:1860-1862
89. Oberholzer AF, Hendriksen C, Monsch AU, et al. Safety and effectiveness of low-dose clozapine in psychogeriatric patients: a preliminary study. Int Psychogeriatr 1992;4:187-195
90. Richards SS, Sweet RA, Ganguli R, et al. Clozapine: acute and maintenance treatment in late-life psychosis [abstract]. Am J Ger Psychiatry 1996;4:377-378
91. Sajatovic M, Jaskiw G, Konicki PE, et al. Outcome of clozapine therapy for elderly patients with refractory primary psychoses. Int J Geriatr Psychiatry 1997;12:553-558
92. Pitner JK, Mintzer JE, Pennypacker LC, et al. Efficacy and adverse effects of clozapine in four elderly psychotic patients. J Clin Psychiatry 1995;56:180-185
93. Chengappa KN, Baker RW, Kreinbrook SB, et al. Clozapine use in female geriatric patients with psychoses. J Geriatr Psychiatry Neurol 1995; 8:12-15
94. Frankenburg FR, Kalunian D. Clozapine in the elderly. J Geriatr Psychiatry Neurol 1994;7:129-132
95. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999;60:107-115
96. Sajatovic M, Ramirez LF, Vernon L, et al. Outcome of risperidone therapy in elderly patients with chronic psychosis. Int J Psychiatry Med 1996;26:309-317
97. Borison RL, Diamond B, Pathiraja A, et al. Pharmacokinetics of risperidone in chronic schizophrenic patients. Psychopharmacol Bull 1994;30: 193-197
98. Satterlee WG, Reams SG, Burns PR, et al. A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer's disease patients [abstract]. Psychopharmacol Bull 1995;31:534
99. Street J, Mitan S, Tamura R, et al. Olanzapine in the treatment of psychosis and behavioral disturbances associated with Alzheimer's disease [abstract]. Presented at the 3rd Congress of European Federation of Neurological Societies; September 19-25, 1998; Seville, Spain
100. Terman LA. Treatment of senile agitation with chlorpromazine. Geriatrics 1955;10:520-522
101. Robinson DB. Evaluation of certain drugs in geriatric patients. Arch Gen Psychiatry 1959;1:41-47
102. Abse DW, Dahlstrom WG, Hill C. The value of chemotherapy in senile mental disturbance. JAMA 1960;174:2036-2042
103. Gottlieb GL, McAllister TW, Gur RC. Depot neuroleptics in the treatment of behavioral disorders in patients with Alzheimer's disease. J Am Geriatr Soc 1988;36:642-644
104. Raskind M, Elvarey C, Herlin RN. Fluphenazine enanthate in the treatment of late paraphrenia. J Am Geriatr Soc 1979;27:459-463
105. Sugarman AA, Williams BH, Adlerstein AM. Haloperidol in the psychiatric disorders of old age. Am J Psychiatry 1964;120:1190-1192
106. Tobin JM, Brousseau ER, Lorenz AA. Clinical evaluation of haloperidol in geriatric patients. Geriatrics 1970;25:119-122
107. Smith GR, Taylor CW, Linkous P. Haloperidol versus thioridazine for the treatment of psychogeriatric patients: a double-blind clinical trial. Psychosomatics 1974;15:134-138
108. Devanand DP, Sackeim HA, Brown RP, et al. A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease. Arch Neurol 1989;46:854-857
109. Carlyle W, Ancill RJ, Shledon L. Aggression in the demented patient: a double-blind study of loxapine versus haloperidol. Int Clin Psychopharmacol 1993;8:103-108
110. Tsuang M, Lu LM, Stotsky BA, et al. Haloperidol versus thioridazine for hospitalized psychogeriatric patients: double-blind study. J Am Geriatr Soc 1971;19:593-600
111. Cowley LM, Glen RS. Double-blind study of thioridazine and haloperidol in geriatric patients with a psychosis associated with organic brain syndrome. J Clin Psychiatry 1979;40:411-419
112. Rosen HJ. Double-blind comparison of haloperidol and thioridazine in geriatric outpatients. J Clin Psychiatry 1979;40:17-20
113. Petrie WM, Ban TA, Berney S. Loxapine in psychogeriatrics: a placebo- and standard-controlled clinical investigation. J Clin Psychopharmacol 1982;2:122-126
114. Steele C, Lucas MJ, Tune L. Haloperidol versus thioridazine in the treatment of behavioral symptoms in senile dementia of the Alzheimer's type: preliminary findings. J Clin Psychiatry 1986;47:310-312
115. Sultzer DL, Gray KF, Gunay I, et al. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry 1997;5:60-69
116. Barnes R, Veith R, Okimoto J. Efficacy of antipsychotic medications in behaviorally disturbed dementia patients. Am J Psychiatry 1982;139: 1170-1174
117. Jackson EB. Mellaril in the treatment of the geriatric patient. Am J Psychiatry 1961;118:543-544
118. Kral VA. The use of thioridazine (Mellaril) in aged people. Can Med Assoc J 1961;84:152-154
119. Cavero CV. Evaluation of thioridazine in the aged. J Am Geriatr Soc 1966;14:617-622
120. Lehmann E, Ban A. Comparative pharmacotherapy of the aging psychotic patient. Laval Med 1967;38:588-595
121. Birkett DP, Boltuch B. Chlorpromazine in geriatric psychiatry. J Am Geriatr Soc 1972;20:403-406
122. Altman H, Mehta B, Evenson RC. Behavioral effects of drug therapy on psychogeriatric inpatients: chlorpromazine and thioridazine. J Am Geriatric 1973;21:241-248
123. Stotsky B. Multicenter study comparing thioridazine with diazepam and placebo in elderly, nonpsychotic patients with emotional and behavioral disorders. Clin Ther 1984;6:546-559
124. Phanjoo AL, Link C. Remoxipride versus thioridazine in elderly psychotic patients. Acta Psychiatr Scand Suppl 1990;358:181-185
125. Rada RT, Kellner R. Thiothixene in the treatment of geriatric patients with chronic organic brain syndrome. J Am Geriatr Soc 1976;3:105-107
126. Finkel SI, Lyons JS, Anderson RL, et al. A randomized, placebo-controlled trial of thiothixene in agitated, demented nursing home patients. Int J Geriatr Psychiatry 1995;10:129-136
127. Hamilton LD, Bennett JL. The use of trifluoperazine in geriatric patients with chronic brain syndrome. J Am Geriatr Soc 1962;10:140-147
128. Salzman C, Satlin A, Burrows AB. Geriatric psychopharmacology. In: Schatzberg AF, Nemeroff CB, eds. The American Psychiatric Press Textbook of Psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press; 1998:961-978
129. Shulman RW, Singh A, Shulman KI. Treatment of elderly institutionalized bipolar patients with clozapine. Psychopharmacol Bull 1997;33: 113-118
130. Reyntjens A. Heylen S, Gelders Y, et al. Risperidone in the treatment of behavioral symptoms in psychogeriatric patients: a pilot clinical investigation [abstract]. Psychopharmacology 1988;96(suppl 1):335
131. Goldberg TE, Berman KF, Weinberger DR. Neuropsychology and neurophysiology of schizophrenia. Curr Opin Psychiatry 1995;8:34-40
132. Marciniak BH, Guay DRP. Risperidone tolerability in the long-term care population. ConsuIt Pharm 1995;10:1274-1278
133. Madhusoodanan S, Brenner R, Araujo L, et al. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry 1995;56:514-518
134. Gierz M, An A, Jeste DV, et al. Use of risperidone in the elderly [poster]. Presented at the 9th annual meeting of the American Association for Geriatric Psychiatry; February 16-19, 1996; Tuscon, Ariz
135. Berman I, Merson A, Sison C, et al. Regional cerebral blood flow changes associated with risperidone treatment in elderly schizophrenia patients a pilot study. Psychopharmacol Bull 1996;32:95-100
136. Jeste DV, Eastham JH, Lacro JP, et al. Management of late-life psychosis. J Clin Psychiatry 1996;57(suppl 3):39-45
137. Kopala LC, Good KP, Honer WG. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. J Clin Psychopharmacol 1997;17:308-313
138. Madhusoodanan S, Brecher M, Brenner R, et al. Efficacy and tolerability of risperidone in elderly patients with psychotic disorders [poster]. Presented at the 10th annual meeting of the American Association for Geriatric Psychiatry; March 2-5, 1997; Lake Buena Vista, Fla
139. Zarate CA Jr, Baldessarini RJ, Siegel AJ, et al. Risperidone in the elderly: a pharmacoepidemiologic study. J Clin Psychiatry 1997;58:311-317
140. Howanitz E, Pardo M, Simelson DA, et al. The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. J Clin Psychiatry 1999;60:41-44